

Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 (CG Docket No. 04–53).

*Number of Petitions Filed: 1.*

**Marlene H. Dortch,**

*Secretary.*

[FR Doc. 04–25743 Filed 11–18–04; 8:45 am]

**BILLING CODE 6712–01–M**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than December 3, 2004.

**A. Federal Reserve Bank of Kansas City** (Donna J. Ward, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. *Embry W. Williams, Jr.*, Amarillo, Texas; to acquire additional voting shares of Union BancShares, Inc., Clayton, New Mexico, and thereby indirectly acquire additional voting shares of First National Bank of New Mexico, Clayton, New Mexico.

Board of Governors of the Federal Reserve System, November 15, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04–25689 Filed 11–18–04; 8:45 am]

**BILLING CODE 6210–01–S**

## FEDERAL RESERVE SYSTEM

### Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y (12 CFR Part 225) to engage *de novo*, or to

acquire or control voting securities or assets of a company, including the companies listed below, that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. The notice also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 3, 2004.

**A. Federal Reserve Bank of Atlanta** (Sue Costello, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303:

1. *DBT Holding Company*, Vidalia, Georgia; to engage *de novo* through its subsidiary, DBW Technologies, LLC, Atlanta, Georgia, in data processing activities, pursuant to section 225.28(b)(14)(i) of Regulation Y.

Board of Governors of the Federal Reserve System, November 15, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04–25690 Filed 11–18–04; 8:45 am]

**BILLING CODE 6210–01–S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Office of the Secretary

#### Findings of Scientific Misconduct

**AGENCY:** Office of the Secretary, HHS.  
**ACTION:** Notice.

**SUMMARY:** Notice is hereby given that the Office of Research Integrity (ORI) and the Acting Assistant Secretary for Health have taken final action in the following case:

*Ali Sultan, M.D., Ph.D., Harvard School of Public Health:* On October 19, 2004, the U.S. Public Health Service (PHS) entered into a Voluntary Exclusion Agreement with the President and Fellows of Harvard College (Harvard) and Ali Sultan, M.D., Ph.D.,

former Assistant Professor of Immunology and Infectious Diseases at the Harvard School of Public Health (HSPH). Based on HSPH's inquiry report, the respondent's admission, and additional analysis conducted by ORI in its oversight review, PHS found that Dr. Sultan engaged in scientific misconduct in research funded by National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), grant 1 P01 AI060332–01, "Chemical genetics and malaria drug development," Subproject 2, "Screening of target-rich environment."

Specifically, PHS and Harvard found that:

- Dr. Ali Sultan plagiarized text, plagiarized three figures showing results of an immunofluorescence assay, a phosphorimage, and northern blot analysis (Figures 3, 4, and 5, respectively), and falsified the data as results of experiments on *Plasmodium bergheii*, instead of *P. falciparum* as reported in a subproject of the PHS grant application 1 P01 AI060332–01, "Chemical genetics and malaria drug development."

- Dr. Ali Sultan fabricated portions of an e-mail from his postdoctoral student that he presented to the HSPH inquiry committee purportedly to falsely implicate the student in the submission of the plagiarized materials for the grant application.

The Voluntary Exclusion Agreement states that for a period of three (3) years, beginning on October 19, 2004:

(1) Dr. Sultan agreed to exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government as defined in the debarment regulations at 45 CFR part 76; and

(2) Dr. Sultan agreed to exclude himself from serving in any advisory capacity to PHS including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

#### FOR FURTHER INFORMATION CONTACT:

Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (301) 443–5330.

Dated: November 10, 2004.

**Chris B. Pascal,**

*Director, Office of Research Integrity.*

[FR Doc. 04–25648 Filed 11–18–04; 8:45 am]

**BILLING CODE 4150–31–P**